Liraglutide is an acylated GLP-1 analog, and its pharmacokinetic and pharmacodynamic properties as a GLP-1R agonist make it an important therapeutic option for many patients with type 2 diabetes (Jacobsen et al., 2016; Khera et al., 2016; Tamborlane et al., 2019). Here, GCG is linked to type 2 diabetes mellitus.